C4 Therapeutics (CCCC) Return on Invested Capital (2022 - 2024)

C4 Therapeutics' (CCCC) quarterly Return on Invested Capital came in at 0.12% in Q1 2024, down 16.52% quarter-over-quarter from 0.1% in Q4 2023.

C4 Therapeutics (CCCC) Return on Invested Capital (2022 - 2024) Analysis & Trends

C4 Therapeutics' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.12% for Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	C4 Therapeutics	460.17 Mn	224.50 Mn	-	-

Download Data